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Abstract
Background: Amiodarone is a widely used antiarrythmic drug, which may produce secondary
effects on the thyroid. In 14–18% of amiodarone-treated patients, there is overt thyroid
dysfunction, usually in the form of amiodarone-induced thyrotoxicosis, which can be difficult to
manage with standard medical treatment.
Case presentation: Presented is the case of a 65-year-old man, under chronic treatment of atrial
fibrillation with amiodarone, who was admitted to the Intensive Care Unit with acute cardio-
respiratory failure and fever. He was recently hospitalized with respiratory distress, attributed to
amiodarone-induced pulmonary fibrosis. Clinical and laboratory investigation revealed
thyrotoxicosis due to amiodarone treatment. He was begun on thionamide, prednisone and beta-
blockers. After a short term improvement of his clinical status the patient underwent percutaneous
tracheotomy due to weaning failure from mechanical ventilation, which led to the development of
recurrent thyrotoxicosis, unresponsive to medical treatment. Finally, the patient developed
multiple organ failure and died, seven days later.
Conclusion: We suggest that percutaneous tracheotomy could precipitate a thyrotoxic crisis,
particularly in non-euthyroid patients suffering from concurrent severe illness and should be
performed only in parallel with emergency thyroid surgery, when indicated.
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Background
Amiodarone is a benzofuranic-derivative iodine-rich drug
widely used for the treatment of tachyarrhythmias. In 14–
18% of amiodarone-treated patients, there is overt thyroid
dysfunction, either amiodarone-induced-thyrotoxicosis
(AIT) or amiodarone-induced-hypothyroidism (AIH) [1].
In contrast to AIH, AIT is a condition difficult to manage,
requiring an aggressive therapy with multiple drugs. We
report a case of a patient with pulmonary fibrosis who was
treated for severe AIT in a multidisciplinary Intensive Care
Unit (ICU) and developed recurrent fatal thyrotoxicosis
after a percutaneous tracheotomy, which was performed
due to weaning failure from mechanical ventilation.
Case presentation
A 65-year-old man was hospitalized with a 1-month his-
tory of exertional shortness of breath and productive
cough. He had a history of coronary artery disease and was
under medical treatment with amiodarone (200 mg/day)
for approximately 4 years, due to recurrent atrial fibrilla-
tion. On his first hospital admission the patient was in
sinus rhythm with 86 beats per minute and blood pres-
sure within normal range. His physical examination
revealed fine, late inspiratory crackles on both lung bases
and no other signs of congestive heart failure. Small bilat-
eral pleural effusions were present on the chest X-ray,
whereas CT scanning of the thorax revealed a pattern of
pulmonary fibrosis that was attributed to chronic amio-
darone treatment, after excluding other causes with
fiberoptic bronchoscopy (bronchoalveolar lavage and
transbronchial biopsy). A myocardial infarction was ruled
out, amiodarone treatment was discontinued and the
patient was discharged on sotalol 120 mg/day.
Twenty four hours later, he was readmitted to the emer-
gency department with fever (up to 38.6°C), severe dysp-
nea and production of pink, frothy sputum. On second
hospital admission the patient was cyanotic, restless and
irritable [arterial blood gases (ABGs) without supplemen-
tal oxygen: pH: 7.49; pO2: 45 mmHg; PCO2: 35 mmHg;
SpO2: 85%], with pulse of 145 beats/min, blood pressure
140/80 mmHg and respiratory rate of 35/min. Physical
examination revealed regular tachycardic rhythm with S3/
S4 gallop, whereas rales presented in all lung fields. His
electrocardiogram (ECG) showed a sinus tachycardia,
without evidence of acute myocardial ischemia. Blood
count and routine serum biochemistry tests were normal.
The patient was intubated and transferred to the ICU,
where he was started on bronchodilators, furosemide diu-
resis and broad spectrum antibiotics (ciprofloxacin plus
amoxycilline/clavulanic acid), as the initial impression
was of an acute pulmonary edema due to decompensated
heart failure or concomitant severe respiratory infection.
However, plasma thyroid function tests were indicative of
severe thyrotoxicosis that was attributed to chronic amio-
darone treatment (Figure 1), [free T4:26 ng/dL, (normal
range: 0.7–1.9); Thyroid Stimulating Hormone (TSH)
<0.01 μIU/ml, (normal range: 0.38–3.80); free T3:9.5 pg/
mL, (normal range: 1.4–3.8)] and he was begun on pro-
pylthiouracil (600 mg, po, tid), prednisone (30 mg, daily,
IV), propranolol (40 mg, qid), furosemide (40 mg/h, IV)
and low molecular weight heparin. At the same time, the
patient remained under sedation with midazolame and
remifentanyl and occasionally, under neuromuscular
block with cis-atracurium. Antithyroglobulin, antimicro-
somal and TSH-receptor antibody results were negative.
The ultrasonography of the thyroid gland was more or less
normal (slightly increased gland size) whereas color flow
Doppler sonography (CFDS) demonstrated a heterogene-
ous pattern with decreased flow.
A slight clinical amelioration was observed a few days
later (Figure 1), while serum free T4 and free T3 decreased
promptly (FT4: 5.5 ng/dL, FT3: 5.13 pg/mL). All blood,
urine and sputum cultures remained negative, whereas
procalcitonin (PCT) and C-reactive protein (CRP) levels
were within normal range. Nevertheless, as the patient
had difficulties in weaning from mechanical ventilation,
he underwent a percutaneous tracheotomy during the
10th day of stay in ICU. Forty eight hours later, he devel-
oped tachycardia and hypotension. His plasma thyroid
function tests were indicative of recurrent thyrotoxicosis
(Figure 1, TSH <0.01 μIU/ml, FT4:14.5 ng/dL, FT3: 6.4 pg/
mL). ST segment depression was observed in all ECG
leads, without an increase on serum myocardial enzymes.
Cultures of different origin remained negative. Deep vein
ultrasonography, D-Dimers assay and transthoracic
echocardiography were negative for pulmonary throm-
boembolism. His ventricular response was unable to con-
trol despite escalating doses of β-blockers, whereas
inotropic support failed to restore the failing circulation.
The patient ultimately developed multiple organ failure
and was pronounced dead seven days later.
Discussion
Since amiodarone was first marketed in 1992 in Japan, the
incidence of amiodarone-induced thyrotoxicosis (AIT)
has been increasing [2]. About 2–12 % of patients treated
with amiodarone develop iodine-induced thyrotoxicosis,
a condition sometimes extremely difficult to manage due
to complex and long elimination half life of amiodarone
[3]. During amiodarone treatment, approximately 7–21
mg iodide is made available each day, releasing 50- to
100-fold excess iodine daily. Furthermore, amiodarone is
distributed in several tissues from which, it is slowly
released, with a terminal elimination half-life of approxi-
mately 52.6 ± 26.7 days and almost two months for its
main metabolite, desethyl-amiodarone (DEA), explaining
the fact that after amiodarone withdrawal, the drug
remains available for a long period [3,4]. In peripheral tis-Journal of Medical Case Reports 2007, 1:134 http://www.jmedicalcasereports.com/content/1/1/134
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sues, amiodarone inhibits type I 5-deiodinase activity,
decreasing peripheral conversion of T4 to T3. In addition,
the drug inhibits thyroid hormone entry into peripheral
tissues. Both mechanisms contribute to an increase in
serum T4 and a decrease in serum T3 concentration in
euthyroid subjects [3,5]. At the same time, amiodarone
causes a biphasic change in serum TSH with an initial
increase and a subsequent normalization of its values in
patients who remain euthyroid, due to an inhibitory effect
on type II 5-deiodinase activity in the pituitary [3]. Sub-
normal or suppressed serum TSH could be indicative of
subclinical thyrotoxicosis during chronic amiodarone
treatment whereas critical non-thyroidal illness is associ-
ated with the same changes in TSH and free T4 levels. Only
a sudden decrease in serum TSH, along with high free T4
and T3concentrations can be useful in establishing the
diagnosis of amiodarone-induced thyrotoxic crisis [6].
Contrary to the effect on the thyroid, amiodarone can
induce a hypothyroid-like state at the tissue level and par-
ticularly in the heart, related to both a reduction in the
number of catecholamine levels and a decrease in the
effect of T3adrenoceptors[3]. Two main forms of AIT have
been described: type I AIT develops in an abnormal thy-
roid gland (nodular goiter, latent Graves' disease) due to
iodine-induced true hyperthyroidism; type II AIT occurs
in an apparently normal thyroid gland and is due to
iodine-induced (or amiodarone -induced) destructive
thyroiditis [1,7] In the first case, iodine load is responsible
for excessive thyroid hormone synthesis and its preva-
lence is higher in mildly iodine deficient areas, suggesting
that patients with preexisting thyroid abnormalities are
unable to adapt normally to an excessive iodine intake
[8]. In the second case, patients usually have no underly-
ing thyroid abnormalities, whereas a markedly increased
serum interleukin 6 (IL-6) concentration, along with his-
topathologic findings demonstrating moderate to severe
follicular damage, support the destructive nature of AIT
type II, which seems to result from discharge of preformed
The fluctuations of thyroid hormones during patient's ICU stay Figure 1
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thyroid hormones from disrupted follicles [3,8]. Useful
tools in differentiating these two types include thyroid
autoimmunity evaluation (positive in type I), thyroid
ultrasonography (usually abnormal in type I), thyroid
color flow Doppler sonography (homogeneous pattern
with increased vascularity in type I and heterogeneous
pattern with low vascularity in type II) and serum IL-6 lev-
els (usually increased in type II) [3]. Eaton et al in a retro-
spective audit of a large cohort of AIT patients
demonstrated that CFDS was the most useful method for
a rapid discrimination between type I and II AIT, whereas
serum IL-6 measurement was unable to differentiate the
two types of amiodarone-induced thyrotoxicosis [9]. Nev-
ertheless, differentiation between these two forms is not
always clear-cut, and most experts believe that mixed (or
indefinite) forms are probably more frequent than previ-
ously recognized (20%) [10] and usually occur in abnor-
mal thyroid glands but with features of destructive
processes [6]. Management of AIT remains a major chal-
lenge and is far more difficult than its diagnosis. Accord-
ing to Eaton, approximately 20% of cases of AIT remit
spontaneously, however, in most instances specific treat-
ment is required in order to limit the deleterious effects of
thyrotoxicosis on the heart. Type I is treated with thiona-
mides, which inhibit synthesis of new thyroid hormones,
either alone or in combination with potassium perchlo-
rate, because it limits further entry of iodine into the thy-
roid [8]. Thyroidectomy represents a valid option for
severe cases refractory to conventional treatment,
although failure to achieve a euthyroid state before sur-
gery may increase the surgical risk [11]. Recently, Bogazzi
et al observed that a short course of iopanoic acid prior to
surgery might help to control rapidly thyrotoxicosis and
reduces the risks of thyroid surgery in patients with heart
disease. The former is an oral cholecystographic agent that
inhibits peripheral monodeiodination of T4 to T3 [12].
The preferred treatment for type II AIT is represented by
glucocorticoides because it is not considered as a true
form of hyperthyroidism, but rather a destructive thy-
roiditis caused by amiodarone and/or iodine. According
to the European Thyroid Association Survey, definite
treatment of thyroid disease (ablative therapy with either
radioiodine or thyroidectomy) will be required in most
cases of type I AIT, while most type II AIT patients will
remain more easily euthyroid after control of thyrotoxico-
sis, because the thyroid gland is basically normal [10].
Nevertheless, in view of diagnostic difficulties, experts
suggest initially treatment of all cases of AIT with a com-
bination of thionamides and glucocorticoids, whereas
patients unresponsive to medical therapy can be managed
with thyroidectomy [10,13,14]. In a recent retrospective
study of 28 cases with AIT, Osman et al found that amio-
darone withdrawn had no adverse influence on response
to treatment of amiodarone-induced thyrotoxicosis while
there were no differences in overall outcome between
types I and II of AIT [15]. In the present case, despite the
fact that serum IL-6 levels were not measured, we sup-
posed that the patient had a dramatic clinical manifesta-
tion of amiodarone-induced thyrotoxicosis type II, as
thyroid autoantibodies and thyroid ultrasonography
examination were indicative of destructive thyroiditis and
there was no previous history of thyroid disease. At the
same time, the region of Thrace, Greece is considered a
geographic area with high iodine intake, making more
unlike the diagnosis of AIT type I.
However, due to the severity of thyrotoxicosis, an aggres-
sive combination pharmacological therapy (beta-block-
ers, thionamides plus glucocorticoides) was started,
which proved to be temporally effective. Despite the mod-
erate decrease in active hormone levels and the initial
amelioration of clinical status, the patient experienced a
new rapid deterioration, refractory to further intensive
medical therapy, after performing a percutaneous trache-
otomy. This procedure aimed at aiding liberation from
mechanical ventilation, as the patient experienced diffi-
culties in weaning, probably because of pre-existing inter-
stitial fibrosis that increases significantly respiratory
system elastance and usually demands the administration
of neuromuscular blockers, in order to achieve effective
ventilation. Their combination with high doses of gluco-
corticoids can decrease muscle strength and affect nega-
tively the weaning outcome [16,17]. Interstitial fibrosis
develops in 0.5–15% of patients with chronic amiodar-
one treatment and if severe enough, is the least likely
abnormality to resolve. Pulmonary toxicity is usually
attributed to direct cytotoxic damage and an indirect
immune reaction due to an amiodarone-induced inhibi-
tion of phospholipase A. The last effect can result in an
accumulation of phospholipids within lysosomes in the
lungs [18]. Patients in whom acute respiratory distress
syndrome (ARDS) [19] develops have the highest mortal-
ity. However, early discontinuation of amiodarone ther-
apy can improve pulmonary function [18]. Since this case
seemed to respond promptly to initial treatment, we did
not consider emergency thyroid surgery as an alternative.
However, after recurrence of thyrotoxicosis following per-
cutaneous tracheotomy, thyroidectomy seemed the only
valid option, despite a non-euthyroid state of the patient
[13]. Unfortunately, we never thought of giving him a
short course of iopanoic acid, aiming at reducing thyro-
toxic symptoms before emergency surgery and the patient
never responded to conventional medical therapy. At the
same time, we think that a definitive treatment, along
with percutaneous tracheotomy should have been sched-
uled in the first place, due to his severe concomitant respi-
ratory disease.Journal of Medical Case Reports 2007, 1:134 http://www.jmedicalcasereports.com/content/1/1/134
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O'Sullivan et al in a retrospective study of 109 patients (60
patients with AIT and 49 with Graves thyrotoxicosis)
found that the co-existence of another severe illness, age
and particularly a severely decreased ventricular function
estimated with echocardiography [left ventricular ejection
fraction (LVEF)<30%], are associated with increased mor-
tality and should urge for aggressive treatment and even
an early thyroid surgery [20]. Transthoracic echocardiog-
raphy that was performed in our patient was indicative of
moderate ventricular dysfunction (LVEF = 40%), however
it is our opinion that AIT, regardless of AIT type, in a sub-
ject with severe concomitant disease should be treated
aggressively, even with early thyroidectomy and particu-
larly in cases who fail to become euthyroid with conven-
tional medical treatment. Whenever needed, surgery can
be performed in parallel with another minimally invasive
procedure, such as a percutaneous tracheotomy.
Conclusion
Urgent non-thyroid surgery can be performed in thyro-
toxic patients, once euthyroidism has been restored [21].
In our case, despite initial amelioration, thyroid function
tests had never been completely normalized, so we
decided to perform a percutaneous instead of an open tra-
cheotomy, under bronchoscopic guidance, limiting surgi-
cal stress as much as possible. There were no
complications, such as hemorrhage or pneumothorax.
Despite near optimum heart rate control with beta-block-
ers (90–100 beats/min), and aggressive pain relief, the
patient's cardiovascular status was dramatically deterio-
rated and serum thyroid hormone concentrations were
indicative of recurrent thyrotoxic storm. Causes other
than thyrotoxicosis were excluded (infection, myocardial
ischemia, thromboembolism) and the patient developed
a few days later, multiple organ failure with fatal outcome.
We conclude that in our opinion, in the ventilator
dependent patient with AIT refractory to conventional
medical treatment and with a concomitant severe illness,
percutaneous tracheotomy should be performed, when-





ICU: intensive care unit
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ECG: electrocardiogram
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